{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T04:19:14Z","timestamp":1791260354842,"version":"4.1.0"},"reference-count":127,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2023,10,29]],"date-time":"2023-10-29T00:00:00Z","timestamp":1698537600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Fundaci\u00f3n de Investigaci\u00f3n Biom\u00e9dica, Hospital Universitario Doce de Octubre, Madrid, Spain"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JPM"],"abstract":"<jats:p>This review of the use of vasopressin aims to be comprehensive and highly practical, based on the available scientific evidence and our extensive clinical experience with the drug. It summarizes controversies about vasopressin use in septic shock and other vasodilatory states. Vasopressin is a natural hormone with powerful vasoconstrictive effects and is responsible for the regulation of plasma osmolality by maintaining fluid homeostasis. Septic shock is defined by the need for vasopressors to correct hypotension and lactic acidosis secondary to infection, with a high mortality rate. The Surviving Sepsis Campaign guidelines recommend vasopressin as a second-line vasopressor, added to norepinephrine. However, these guidelines do not address specific debates surrounding the use of vasopressin in real-world clinical practice.<\/jats:p>","DOI":"10.3390\/jpm13111548","type":"journal-article","created":{"date-parts":[[2023,10,29]],"date-time":"2023-10-29T05:01:08Z","timestamp":1698555668000},"page":"1548","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Vasopressin in Sepsis and Other Shock States: State of the Art"],"prefix":"10.3390","volume":"13","author":[{"given":"Raquel","family":"Garc\u00eda-\u00c1lvarez","sequence":"first","affiliation":[{"name":"Department of Anesthesiology and Surgical Intensive Care, University Hospital 12 de Octubre, 28022 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Arboleda-Salazar","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology and Surgical Intensive Care, University Hospital 12 de Octubre, 28022 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,10,29]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1113\/jphysiol.1895.sp000565","article-title":"On the Physiological Action of Extracts of Pituitary Body and Certain Other Glandular Organs: Preliminary Communication","volume":"18","author":"Oliver","year":"1895","journal-title":"J. Physiol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1097\/00000542-200609000-00004","article-title":"A Century of Arginine Vasopressin Research Leading to New Therapeutic Strategies","volume":"105","author":"Lindner","year":"2006","journal-title":"Anesthesiology"},{"key":"ref_3","first-page":"75","article-title":"Treatment of Diabetes Insipidus with 1-Deamino-8-d-Arginine Vasopressin","volume":"32","author":"Mezei","year":"1975","journal-title":"Acta Med. Acad. Sci. Hung."},{"key":"ref_4","first-page":"917","article-title":"The Use of Surgical Pituitrin in the Control of Esophageal Varix Bleeding; an Experimental Study and Report of Two Cases","volume":"39","author":"Kehne","year":"1956","journal-title":"Surgery"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"245","DOI":"10.4097\/kjae.2017.70.3.245","article-title":"Role of Vasopressin in Current Anesthetic Practice","volume":"70","author":"Park","year":"2017","journal-title":"Korean J. Anesthesiol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1097\/01.CCM.0000063046.82359.4A","article-title":"Circulating Vasopressin Levels in Septic Shock","volume":"31","author":"Sharshar","year":"2003","journal-title":"Crit. Care Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1378\/chest.120.3.989","article-title":"Physiology of Vasopressin Relevant to Management of Septic Shock","volume":"120","author":"Holmes","year":"2001","journal-title":"Chest"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1097\/00000542-200609000-00026","article-title":"The Vasopressin System","volume":"105","author":"Treschan","year":"2006","journal-title":"Anesthesiology"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1152\/physrev.1983.63.4.1243","article-title":"Central Nervous System Mediators of Vasopressin Release","volume":"63","author":"Sklar","year":"1983","journal-title":"Physiol. Rev."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/0014-2999(95)00343-J","article-title":"Comparison of Responses of Canine Pulmonary Artery and Vein to Angiotensin II, Bradykinin and Vasopressin","volume":"282","author":"Sai","year":"1995","journal-title":"Eur. J. Pharmacol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1590\/S0066-782X2003000500002","article-title":"Effect of Arginine Vasopressin on the Canine Epicardial Coronary Artery: Experiments on V1-Receptor-Mediated Production of Nitric Oxide","volume":"80","author":"Evora","year":"2003","journal-title":"Arq. Bras. Cardiol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s11102-015-0703-0","article-title":"Arginine Vasopressin (AVP): A Review of Its Historical Perspectives, Current Research and Multifunctional Role in the Hypothalamo-Hypophysial System","volume":"19","author":"Rotondo","year":"2016","journal-title":"Pituitary"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s13613-020-0628-2","article-title":"Vasopressin and Its Analogues in Shock States: A Review","volume":"10","author":"Demiselle","year":"2020","journal-title":"Ann. Intensive Care"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/S0008-6363(01)00337-6","article-title":"The V2 Vasopressin Receptor Mutations and Fluid Homeostasis","volume":"51","author":"Birnbaumer","year":"2001","journal-title":"Cardiovasc. Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1210\/jc.2002-020791","article-title":"Central Diabetes Insipidus and Autoimmunity: Relationship between the Occurrence of Antibodies to Arginine Vasopressin-Secreting Cells and Clinical, Immunological, and Radiological Features in a Large Cohort of Patients with Central Diabetes Insipidus of Known and Unknown Etiology","volume":"88","author":"Pivonello","year":"2003","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"104093","DOI":"10.1016\/j.lpm.2021.104093","article-title":"Diabetes Insipidus","volume":"50","author":"Gaisl","year":"2021","journal-title":"Presse Medicale Paris Fr."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1097\/SHK.0000000000000864","article-title":"Neuroendocrine Derangements in Early Septic Shock: Pharmacotherapy for Relative Adrenal and Vasopressin Insufficiency","volume":"48","author":"Schurr","year":"2017","journal-title":"Shock Augusta Ga"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1159\/000318531","article-title":"Vasopressin and Its Immune Effects in Septic Shock","volume":"2","author":"Russell","year":"2010","journal-title":"J. Innate Immun."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1097\/00003643-199703001-00003","article-title":"Review of Clinical Experience of Desmopressin in Patients with Congenital and Acquired Bleeding Disorders","volume":"14","author":"Cattaneo","year":"1997","journal-title":"Eur. J. Anaesthesiol. Suppl."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Glava\u0161, M., Gitlin-Domagalska, A., D\u0119bowski, D., Ptaszy\u0144ska, N., \u0141\u0119gowska, A., and Rolka, K. (2022). Vasopressin and Its Analogues: From Natural Hormones to Multitasking Peptides. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23063068"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1007\/s00134-021-06506-y","article-title":"Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021","volume":"47","author":"Evans","year":"2021","journal-title":"Intensive Care Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1007\/s00134-018-5290-x","article-title":"Terlipressin or Norepinephrine, or Both in Septic Shock?","volume":"44","author":"Gordon","year":"2018","journal-title":"Intensive Care Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1007\/s00134-018-5267-9","article-title":"Terlipressin versus Norepinephrine as Infusion in Patients with Septic Shock: A Multicentre, Randomised, Double-Blinded Trial","volume":"44","author":"Liu","year":"2018","journal-title":"Intensive Care Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1001\/jama.2019.14607","article-title":"Effect of Selepressin vs Placebo on Ventilator- and Vasopressor-Free Days in Patients with Septic Shock: The SEPSIS-ACT Randomized Clinical Trial","volume":"322","author":"Laterre","year":"2019","journal-title":"JAMA"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1046\/j.1365-2508.1999.00246.x","article-title":"Adhesions after Laparoscopic Myomectomy: Effect of the Technique Used: ADHESIONS AFTER LAPAROSCOPIC MYOMECTOMY","volume":"8","author":"Assaf","year":"1999","journal-title":"Gynaecol. Endosc."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"100236","DOI":"10.1016\/j.aohep.2020.07.008","article-title":"An Integrated Review of the Hepatorenal Syndrome","volume":"22","author":"Piano","year":"2021","journal-title":"Ann. Hepatol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1001\/jama.2016.0287","article-title":"The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)","volume":"315","author":"Singer","year":"2016","journal-title":"JAMA"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S1473-3099(15)70112-X","article-title":"Sepsis: A Roadmap for Future Research","volume":"15","author":"Cohen","year":"2015","journal-title":"Lancet Infect. Dis."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/S2213-2600(14)70061-X","article-title":"Assessment of the Worldwide Burden of Critical Illness: The Intensive Care Over Nations (ICON) Audit","volume":"2","author":"Vincent","year":"2014","journal-title":"Lancet Respir. Med."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Gamper, G., Havel, C., Arrich, J., Losert, H., Pace, N.L., M\u00fcllner, M., and Herkner, H. Vasopressors for Hypotensive Shock. Cochrane Database Syst. Rev., 2016.","DOI":"10.1002\/14651858.CD003709.pub4"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/S0140-6736(07)61344-0","article-title":"Norepinephrine plus Dobutamine versus Epinephrine Alone for Management of Septic Shock: A Randomised Trial","volume":"370","author":"Annane","year":"2007","journal-title":"Lancet Lond. Engl."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1056\/NEJMoa067373","article-title":"Vasopressin versus Norepinephrine Infusion in Patients with Septic Shock","volume":"358","author":"Russell","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1001\/jama.2016.10485","article-title":"Effect of Early Vasopressin vs Norepinephrine on Kidney Failure in Patients with Septic Shock: The VANISH Randomized Clinical Trial","volume":"316","author":"Gordon","year":"2016","journal-title":"JAMA"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1056\/NEJMoa0907118","article-title":"Comparison of Dopamine and Norepinephrine in the Treatment of Shock","volume":"362","author":"Biston","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1056\/NEJMoa1704154","article-title":"Angiotensin II for the Treatment of Vasodilatory Shock","volume":"377","author":"Khanna","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1007\/s00134-008-1219-0","article-title":"CAT Study investigators A Comparison of Epinephrine and Norepinephrine in Critically Ill Patients","volume":"34","author":"Myburgh","year":"2008","journal-title":"Intensive Care Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.mcna.2020.02.011","article-title":"Sepsis and Septic Shock\u2014Basics of Diagnosis, Pathophysiology and Clinical Decision Making","volume":"104","author":"Font","year":"2020","journal-title":"Med. Clin. N. Am."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S0140-6736(18)30696-2","article-title":"Sepsis and Septic Shock","volume":"392","author":"Cecconi","year":"2018","journal-title":"Lancet"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1056\/NEJMra021333","article-title":"The Pathophysiology and Treatment of Sepsis","volume":"348","author":"Hotchkiss","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1001\/jama.2011.1829","article-title":"Immunosuppression in Patients Who Die of Sepsis and Multiple Organ Failure","volume":"306","author":"Boomer","year":"2011","journal-title":"JAMA"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1146\/annurev-physiol-061121-040214","article-title":"Sepsis-Induced Immunosuppression","volume":"84","author":"Torres","year":"2022","journal-title":"Annu. Rev. Physiol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1038\/nri3552","article-title":"Sepsis-Induced Immunosuppression: From Cellular Dysfunctions to Immunotherapy","volume":"13","author":"Hotchkiss","year":"2013","journal-title":"Nat. Rev. Immunol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1056\/NEJMcibr1004371","article-title":"Immunotherapy for Sepsis\u2014A New Approach against an Ancient Foe","volume":"363","author":"Hotchkiss","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1056\/NEJMra1208623","article-title":"Severe Sepsis and Septic Shock","volume":"369","author":"Angus","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.ccc.2017.08.005","article-title":"Pathophysiology of Septic Shock","volume":"34","author":"Russell","year":"2018","journal-title":"Crit. Care Clin."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/S0272-5231(05)70318-X","article-title":"Nitric oxide in sepsis","volume":"17","author":"Payen","year":"1996","journal-title":"Clin. Chest Med."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"e12703","DOI":"10.1111\/micc.12703","article-title":"Role of TRPV4 Channel in Vasodilation and Neovascularization","volume":"28","author":"Chen","year":"2021","journal-title":"Microcirculation"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1007\/s001340101014","article-title":"The Effects of Vasopressin on Hemodynamics and Renal Function in Severe Septic Shock: A Case Series","volume":"27","author":"Holmes","year":"2001","journal-title":"Intensive Care Med."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1097\/00000542-200203000-00011","article-title":"Beneficial Effects of Short-Term Vasopressin Infusion during Severe Septic Shock","volume":"96","author":"Patel","year":"2002","journal-title":"Anesthesiology"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1161\/01.CIR.0000066692.71008.BB","article-title":"Arginine Vasopressin in Advanced Vasodilatory Shock: A Prospective, Randomized, Controlled Study","volume":"107","author":"Mayr","year":"2003","journal-title":"Circulation"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"R117","DOI":"10.1186\/cc12789","article-title":"Cardiac Ischemia in Patients with Septic Shock Randomized to Vasopressin or Norepinephrine","volume":"17","author":"Mehta","year":"2013","journal-title":"Crit. Care Lond. Engl."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1177\/1074248414559838","article-title":"Pharmacotherapy Update on the Use of Vasopressors and Inotropes in the Intensive Care Unit","volume":"20","author":"Jentzer","year":"2015","journal-title":"J. Cardiovasc. Pharmacol. Ther."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.chest.2017.12.021","article-title":"Management of Refractory Vasodilatory Shock","volume":"154","author":"Jentzer","year":"2018","journal-title":"Chest"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1097\/00003246-199708000-00012","article-title":"Vasopressin Pressor Hypersensitivity in Vasodilatory Septic Shock: Crit","volume":"25","author":"Landry","year":"1997","journal-title":"Care Med."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1161\/01.CIR.95.5.1122","article-title":"Vasopressin Deficiency Contributes to the Vasodilation of Septic Shock","volume":"95","author":"Landry","year":"1997","journal-title":"Circulation"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jcrc.2020.10.023","article-title":"Predictors of Dysrhythmias with Norepinephrine Use in Septic Shock","volume":"61","author":"Wieruszewski","year":"2021","journal-title":"J. Crit. Care"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.jcrc.2020.02.014","article-title":"Relationship between Norepinephrine Dose, Tachycardia and Outcome in Septic Shock: A Multicentre Evaluation","volume":"57","author":"Domizi","year":"2020","journal-title":"J. Crit. Care"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s13613-022-01021-9","article-title":"Timing of Vasoactive Agents and Corticosteroid Initiation in Septic Shock","volume":"12","author":"Ammar","year":"2022","journal-title":"Ann. Intensive Care"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1097\/SHK.0000000000000426","article-title":"NOREPINEPHRINE: NOT TOO MUCH, TOO LONG","volume":"44","author":"Martin","year":"2015","journal-title":"Shock Augusta Ga"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1164\/rccm.202002-0339OC","article-title":"Norepinephrine Dysregulates the Immune Response and Compromises Host Defense during Sepsis","volume":"202","author":"Stolk","year":"2020","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1097\/01.CCM.0000251127.45385.CD","article-title":"Vasopressin: Mechanisms of Action on the Vasculature in Health and in Septic Shock","volume":"35","author":"Barrett","year":"2007","journal-title":"Crit. Care Med."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1038\/sj.bjp.0706065","article-title":"The Pore-Forming Subunit of the K(ATP) Channel Is an Important Molecular Target for LPS-Induced Vascular Hyporeactivity in Vitro","volume":"144","author":"Thakur","year":"2005","journal-title":"Br. J. Pharmacol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1177\/08850666221081836","article-title":"Influence of Timing and Catecholamine Requirements on Vasopressin Responsiveness in Critically Ill Patients with Septic Shock","volume":"37","author":"Jakowenko","year":"2022","journal-title":"J. Intensive Care Med."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1097\/CCM.0000000000002323","article-title":"Vasopressin and Septic Shock Trial (VASST) Group The Septic Shock 3.0 Definition and Trials: A Vasopressin and Septic Shock Trial Experience","volume":"45","author":"Russell","year":"2017","journal-title":"Crit. Care Med."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.ccc.2018.11.004","article-title":"Vasopressin in Vasodilatory Shock","volume":"35","author":"Ukor","year":"2019","journal-title":"Crit. Care Clin."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1097\/CCM.0000000000005317","article-title":"Association of Catecholamine Dose, Lactate, and Shock Duration at Vasopressin Initiation with Mortality in Patients with Septic Shock","volume":"50","author":"Sacha","year":"2022","journal-title":"Crit. Care Med."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1001\/jama.2018.4528","article-title":"Association of Vasopressin Plus Catecholamine Vasopressors vs Catecholamines Alone with Atrial Fibrillation in Patients with Distributive Shock: A Systematic Review and Meta-Analysis","volume":"319","author":"McIntyre","year":"2018","journal-title":"JAMA"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1007\/s00134-019-05620-2","article-title":"Vasopressin in Septic Shock: An Individual Patient Data Meta-Analysis of Randomised Controlled Trials","volume":"45","author":"Nagendran","year":"2019","journal-title":"Intensive Care Med."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1007\/s10557-020-06998-8","article-title":"Vasopressin in Patients with Septic Shock and Dynamic Left Ventricular Outflow Tract Obstruction","volume":"34","author":"Balik","year":"2020","journal-title":"Cardiovasc. Drugs Ther."},{"key":"ref_70","first-page":"293","article-title":"Prognostic Factors in Acute Renal Failure Due to Sepsis. Results of a Prospective Multicentre Study. The French Study Group on Acute Renal Failure","volume":"11","author":"Neveu","year":"1996","journal-title":"Nephrol. Dial. Transplant. Off. Publ. Eur. Dial. Transpl. Assoc. Eur. Ren. Assoc."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"059","DOI":"10.1055\/s-0040-1710320","article-title":"Vasopressor Therapy in the Intensive Care Unit","volume":"42","author":"Russell","year":"2021","journal-title":"Semin. Respir. Crit. Care Med."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1007\/s00134-006-0378-0","article-title":"Vasopressin or Norepinephrine in Early Hyperdynamic Septic Shock: A Randomized Clinical Trial","volume":"32","author":"Lauzier","year":"2006","journal-title":"Intensive Care Med."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s00134-009-1687-x","article-title":"The Effects of Vasopressin on Acute Kidney Injury in Septic Shock","volume":"36","author":"Gordon","year":"2010","journal-title":"Intensive Care Med."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"R204","DOI":"10.1186\/cc2872","article-title":"Acute Dialysis Quality Initiative workgroup Acute Renal Failure\u2014Definition, Outcome Measures, Animal Models, Fluid Therapy and Information Technology Needs: The Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group","volume":"8","author":"Bellomo","year":"2004","journal-title":"Crit. Care Lond. Engl."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"e44","DOI":"10.1097\/CCM.0000000000003471","article-title":"Renal Outcomes of Vasopressin and Its Analogs in Distributive Shock: A Systematic Review and Meta-Analysis of Randomized Trials","volume":"47","author":"Nedel","year":"2019","journal-title":"Crit. Care Med."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.jcrc.2019.11.004","article-title":"Delayed Vasopressor Initiation Is Associated with Increased Mortality in Patients with Septic Shock","volume":"55","author":"Patel","year":"2020","journal-title":"J. Crit. Care"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1186\/s13054-014-0532-y","article-title":"Early versus Delayed Administration of Norepinephrine in Patients with Septic Shock","volume":"18","author":"Bai","year":"2014","journal-title":"Crit. Care Lond. Engl."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1002\/phar.2105","article-title":"Prospective Open-Label Trial of Early Concomitant Vasopressin and Norepinephrine Therapy versus Initial Norepinephrine Monotherapy in Septic Shock","volume":"38","author":"Hammond","year":"2018","journal-title":"Pharmacotherapy"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1067\/mai.2002.122154","article-title":"Glucocorticoid Effects on the Beta-Adrenergic Receptor-Adenylyl Cyclase System of Human Airway Epithelium","volume":"109","author":"Aksoy","year":"2002","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1097\/01.shk.0000235140.97903.90","article-title":"Methylprednisolone Reverses Vasopressin Hyporesponsiveness in Ovine Endotoxemia","volume":"27","author":"Ertmer","year":"2007","journal-title":"Shock Augusta Ga"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1186\/cc8224","article-title":"Bench-to-Bedside Review: Vasopressin in the Management of Septic Shock","volume":"15","author":"Russell","year":"2011","journal-title":"Crit. Care Lond. Engl."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1097\/CCM.0b013e31819879c1","article-title":"Vasopressin plus Corticosteroids: The Shock Duo! Crit","volume":"37","author":"Annane","year":"2009","journal-title":"Care Med."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.jcrc.2021.11.016","article-title":"An International Survey of Adherence to Surviving Sepsis Campaign Guidelines 2016 Regarding Fluid Resuscitation and Vasopressors in the Initial Management of Septic Shock","volume":"68","author":"Bitton","year":"2022","journal-title":"J. Crit. Care"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1007\/s00134-022-06652-x","article-title":"Dose of Norepinephrine: The Devil Is in the Details","volume":"48","author":"Leone","year":"2022","journal-title":"Intensive Care Med."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1186\/s13054-023-04404-x","article-title":"Response to: Norepinephrine Formulation for Equivalent Vasopressive Score","volume":"27","author":"Kotani","year":"2023","journal-title":"Crit. Care Lond. Engl."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1186\/s13054-019-2420-y","article-title":"Broad Spectrum Vasopressors: A New Approach to the Initial Management of Septic Shock?","volume":"23","author":"Chawla","year":"2019","journal-title":"Crit. Care Lond. Engl."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/s13054-022-03911-7","article-title":"Vasopressor Choice and Timing in Vasodilatory Shock","volume":"26","author":"Wieruszewski","year":"2022","journal-title":"Crit. Care Lond. Engl."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1002\/jac5.1079","article-title":"Perceptions Regarding Vasopressin Use and Practices in Septic Shock, and Cost Containment Strategies","volume":"2","author":"Hammond","year":"2019","journal-title":"JACCP J. Am. Coll. Clin. Pharm."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1097\/SHK.0000000000001609","article-title":"Abrupt Discontinuation Versus Down-Titration of Vasopressin in Patients Recovering from Septic Shock","volume":"55","author":"Lam","year":"2021","journal-title":"Shock"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1177\/0885066617714209","article-title":"Discontinuation of Vasopressin Before Norepinephrine in the Recovery Phase of Septic Shock","volume":"34","author":"Hammond","year":"2019","journal-title":"J. Intensive Care Med."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.hrtlng.2019.05.007","article-title":"Effects of the Discontinuation Sequence of Norepinephrine and Vasopressin on Hypotension Incidence in Patients with Septic Shock: A Meta-Analysis","volume":"48","author":"Duclos","year":"2019","journal-title":"Heart Lung J. Crit. Care"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1177\/0885066617716396","article-title":"Hemodynamic Instability Secondary to Vasopressin withdrawal in Septic Shock","volume":"34","author":"Bissell","year":"2019","journal-title":"J. Intensive Care Med."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1097\/01.CCM.0000281853.50661.23","article-title":"Comparison of Two Dose Regimens of Arginine Vasopressin in Advanced Vasodilatory Shock","volume":"35","author":"Luckner","year":"2007","journal-title":"Crit. Care Med."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1177\/08850666221118282","article-title":"Vasopressin Response and Clinical Trajectory in Septic Shock Patients","volume":"38","author":"Bauer","year":"2023","journal-title":"J. Intensive Care Med."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.jcrc.2019.10.005","article-title":"Cost-Effectiveness of Second-Line Vasopressors for the Treatment of Septic Shock","volume":"55","author":"Lam","year":"2020","journal-title":"J. Crit. Care"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1177\/1060028020901521","article-title":"Narrative Review of Controversies Involving Vasopressin Use in Septic Shock and Practical Considerations","volume":"54","author":"Hammond","year":"2020","journal-title":"Ann. Pharmacother."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1097\/SHK.0000000000001086","article-title":"Body Mass\u2019s Impact on Response to Fixed-Dose Vasopressin in Patients with Septic Shock","volume":"50","author":"Torbic","year":"2018","journal-title":"Shock"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1177\/1060028016656384","article-title":"Effect of Body Weight on Hemodynamic Response in Patients Receiving Fixed-Dose Vasopressin for Septic Shock","volume":"50","author":"Hodge","year":"2016","journal-title":"Ann. Pharmacother."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"2659","DOI":"10.1097\/01.CCM.0000186749.34028.40","article-title":"Arginine Vasopressin in 316 Patients with Advanced Vasodilatory Shock","volume":"33","author":"Luckner","year":"2005","journal-title":"Crit. Care Med."},{"key":"ref_100","doi-asserted-by":"crossref","unstructured":"Baghela, A., Pena, O.M., Lee, A.H., Baquir, B., Falsafi, R., An, A., Farmer, S.W., Hurlburt, A., Mondragon-Cardona, A., and Rivera, J.D. (2022). Predicting Sepsis Severity at First Clinical Presentation: The Role of Endotypes and Mechanistic Signatures. EBioMedicine, 75.","DOI":"10.1016\/j.ebiom.2021.103776"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1164\/rccm.200903-0332OC","article-title":"Beta2-Adrenergic Receptor Gene Polymorphism Is Associated with Mortality in Septic Shock","volume":"181","author":"Nakada","year":"2010","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1378\/chest.10-2517","article-title":"Leucyl\/Cystinyl Aminopeptidase Gene Variants in Septic Shock","volume":"139","author":"Nakada","year":"2011","journal-title":"Chest"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"S609","DOI":"10.1097\/01.CCM.0000279158.51481.41","article-title":"Vasopressin in Septic Shock: Crit","volume":"35","author":"Russell","year":"2007","journal-title":"Care Med."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1097\/CCM.0000000000003544","article-title":"Renin as a Marker of Tissue-Perfusion and Prognosis in Critically Ill Patients","volume":"47","author":"Gleeson","year":"2019","journal-title":"Crit. Care Med."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1164\/rccm.201911-2172OC","article-title":"Renin and Survival in Patients Given Angiotensin II for Catecholamine-Resistant Vasodilatory Shock. A Clinical Trial","volume":"202","author":"Bellomo","year":"2020","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1161\/CIRCULATIONAHA.108.814533","article-title":"Early On-Cardiopulmonary Bypass Hypotension and Other Factors Associated with Vasoplegic Syndrome","volume":"120","author":"Levin","year":"2009","journal-title":"Circulation"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1097\/MAJ.0000000000000341","article-title":"Cardiac Vasoplegia Syndrome: Pathophysiology, Risk Factors and Treatment","volume":"349","author":"Omar","year":"2015","journal-title":"Am. J. Med. Sci."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/S0022-5223(98)70049-2","article-title":"Management of Vasodilatory Shock after Cardiac Surgery: Identification of Predisposing Factors and Use of a Novel Pressor Agent","volume":"116","author":"Argenziano","year":"1998","journal-title":"J. Thorac. Cardiovasc. Surg."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/S0003-4975(96)00931-9","article-title":"Cytokine Responses to Cardiopulmonary Bypass: Lessons Learned from Cardiac Transplantation","volume":"63","author":"Wan","year":"1997","journal-title":"Ann. Thorac. Surg."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1016\/0003-4975(92)90113-I","article-title":"Release of Vasoactive Substances during Cardiopulmonary Bypass","volume":"54","author":"Downing","year":"1992","journal-title":"Ann. Thorac. Surg."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/0003-4975(91)90302-7","article-title":"Prospects for Understanding and Eliminating the Deleterious Effects of Cardiopulmonary Bypass","volume":"51","author":"Kirklin","year":"1991","journal-title":"Ann. Thorac. Surg."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s00134-008-1279-1","article-title":"The Vasopressin and Copeptin Response in Patients with Vasodilatory Shock after Cardiac Surgery: A Prospective, Controlled Study","volume":"35","author":"Jochberger","year":"2009","journal-title":"Intensive Care Med."},{"key":"ref_113","first-page":"3030","article-title":"Copeptin: A Diagnostic Factor for Critical Patients","volume":"19","author":"Yilman","year":"2015","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"ref_114","first-page":"2259","article-title":"Low Cardiac Output Stimulates Vasopressin Release in Patients with Stage d Heart Failure","volume":"78","author":"Imamura","year":"2014","journal-title":"Circ. J. Off. J. Jpn. Circ. Soc."},{"key":"ref_115","first-page":"II-286","article-title":"A Prospective Randomized Trial of Arginine Vasopressin in the Treatment of Vasodilatory Shock after Left Ventricular Assist Device Placement","volume":"96","author":"Argenziano","year":"1997","journal-title":"Circulation"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1053\/j.jvca.2018.04.006","article-title":"Vasopressin in Cardiac Surgery: A Meta-Analysis of Randomized Controlled Trials","volume":"32","author":"Bouvet","year":"2018","journal-title":"J. Cardiothorac. Vasc. Anesth."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1097\/ALN.0000000000001434","article-title":"Vasopressin versus Norepinephrine in Patients with Vasoplegic Shock after Cardiac Surgery: The VANCS Randomized Controlled Trial","volume":"126","author":"Hajjar","year":"2017","journal-title":"Anesthesiology"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1053\/j.jvca.2014.07.007","article-title":"Vasopressin Does Not Raise Cardiac Enzymes Following Cardiac Surgery: A Randomized Double-Blind Clinical Trial","volume":"29","author":"Okamoto","year":"2015","journal-title":"J. Cardiothorac. Vasc. Anesth."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/j.jcrc.2015.06.013","article-title":"Intraoperative Administration of Vasopressin during Coronary Artery Bypass Surgery Is Associated with Acute Postoperative Kidney Injury","volume":"30","author":"Porhomayon","year":"2015","journal-title":"J. Crit. Care"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1111\/jocs.12242","article-title":"Vasopressin Induces Rectosigmoidal Mucosal Ischemia during Cardiopulmonary Bypass","volume":"29","author":"Bomberg","year":"2014","journal-title":"J. Card. Surg."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1053\/j.jvca.2020.11.032","article-title":"Vasopressor Therapy in Cardiac Surgery-An Experts\u2019 Consensus Statement","volume":"35","author":"Guarracino","year":"2021","journal-title":"J. Cardiothorac. Vasc. Anesth."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1177\/0885066620917630","article-title":"Vasopressor and Inotrope Therapy in Cardiac Critical Care","volume":"36","author":"Jentzer","year":"2021","journal-title":"J. Intensive Care Med."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1213\/00000539-197554040-00019","article-title":"Effects of Hemodilution on Hypotention during Cardiopulmonary Bypass","volume":"54","author":"Gordon","year":"1975","journal-title":"Anesth. Analg."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"A80","DOI":"10.1016\/j.resuscitation.2020.09.012","article-title":"Adult Advanced Life Support: 2020 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science with Treatment Recommendations","volume":"156","author":"Soar","year":"2020","journal-title":"Resuscitation"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.resuscitation.2019.04.008","article-title":"Vasopressors during Adult Cardiac Arrest: A Systematic Review and Meta-Analysis","volume":"139","author":"Holmberg","year":"2019","journal-title":"Resuscitation"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1213\/01.ANE.0000087039.60041.2E","article-title":"The Effects of Vasopressin on Systemic and Splanchnic Hemodynamics and Metabolism in Endotoxin Shock","volume":"97","author":"Martikainen","year":"2003","journal-title":"Anesth. Analg."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1097\/01.CCM.0000059722.94182.79","article-title":"Ischemic Skin Lesions as a Complication of Continuous Vasopressin Infusion in Catecholamine-Resistant Vasodilatory Shock: Incidence and Risk Factors","volume":"31","author":"Mayr","year":"2003","journal-title":"Crit. Care Med."}],"container-title":["Journal of Personalized Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4426\/13\/11\/1548\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T21:13:38Z","timestamp":1760130818000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4426\/13\/11\/1548"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,29]]},"references-count":127,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2023,11]]}},"alternative-id":["jpm13111548"],"URL":"https:\/\/doi.org\/10.3390\/jpm13111548","relation":{},"ISSN":["2075-4426"],"issn-type":[{"value":"2075-4426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,29]]}}}